News archive

November 2012

• • 6 November 2012
  • Crown Bioscience

  Crown Bioscience, Inc. and Horizon Discovery, Ltd. to Showcase X-MAN Cell Lines for In Vivo and In Vitro Drug Discove...

  High-quality human disease models are crucial for generating ‘first-in-class’ patient-relevant targets and facilitating the development of novel oncology targets and early-stage drug discovery prog...

June 2012

• • 27 June 2012
  • KBI Biopharma

  Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic

  Lubris Achieves Over Gram per Liter of Recombinant Human Lubricin Using Selexis SUREtechnology Platform

• • 6 June 2012
  • KBI Biopharma

  Irvine Scientific Launches BalanCD CHO SLX A Culture Media Developed for the Selexis SURE CHO-M Cell Line

  The New Media Improves SURE CHO-M Productivity

May 2012

• • 23 May 2012
  • KBI Biopharma

  Selexis SA and Fusion Antibodies Services Form Partnership to Speed Therapeutic Monoclonal Antibody Development

  Customers will be able to seamlessly go from non-human MAbs to clinical candidate generated in a cGMP-ready CHO cell line in 8 months.

• • 15 May 2012
  • KBI Biopharma

  Selexis and Neogenix Oncology Execute Commercial License Agreement

  "Selexis expertise will be an added value for our molecule,” said Antonio Francesco Di Naro, PhD, Founder, and CEO of ADIENNE Pharma & Biotech. “This collaboration will be fruitful for our company.”

January 2012

• • 11 January 2012
  • Crown Bioscience

  Crown Bioscience, Inc. Enters into Strategic Partnership with Jiangsu Hengrui Medicine Co., Ltd. for the Discovery an...

  With this partnership, Crown Biologics will lead the discovery program and deliver a humanized therapeutic antibody IND candidate.